Belantamab mafodotin is a medication used in this clinical trial to treat multiple myeloma, a type of blood cancer. It works by targeting and attaching to a specific protein found on the surface of cancer cells. Once attached, it delivers a toxic substance directly into the cancer cells, helping to kill them and slow down the progression of the disease.

Lenalidomide is another medication used in the trial, which helps to treat multiple myeloma by affecting the immune system. It works by enhancing the body’s immune response to fight cancer cells and also by directly attacking the cancer cells to prevent them from growing and spreading.

Dexamethasone is a type of steroid medication included in the trial. It helps reduce inflammation and suppresses the immune system, which can be beneficial in treating multiple myeloma. It is often used in combination with other cancer treatments to enhance their effectiveness.

Daratumumab is a medication used in the trial that targets a specific protein on the surface of multiple myeloma cells. By binding to this protein, it helps the immune system to identify and destroy the cancer cells. This medication is used to help control the disease and improve patient outcomes.

Multiple myeloma – Multiple myeloma is a type of blood cancer that affects plasma cells, which are a type of white blood cell found in the bone marrow. It begins when a single plasma cell becomes abnormal and starts to multiply uncontrollably, leading to an accumulation of abnormal cells in the bone marrow. These abnormal cells produce a large amount of a single type of antibody, which can cause damage to the bones and interfere with the production of normal blood cells. As the disease progresses, it can lead to bone pain, fractures, anemia, kidney dysfunction, and increased susceptibility to infections. The disease often progresses in a series of relapses and remissions, with periods of active disease followed by periods of stability. Over time, the disease can become more aggressive and resistant to treatment.